While many life science cluster markets continue to struggle with the effects of elevated deliveries and softer demand, several are beginning to show signs of stabilization. The DC–Baltimore cluster is one of these markets beginning to recover.
After nearly a year with no meaningful new construction deliveries, vacant space has stopped growing, suggesting the market may be entering the early stages of recovery. Occupancy reached 83% in the first quarter of 2026, supported by positive net absorption.
Big pharma manufacturing in the region will likely contribute to future growth. In one of the largest life science real estate transactions of 2026, Samsung Biologics acquired a 400K square foot manufacturing facility in Rockville from GSK and plans to establish significant manufacturing operations there. AstraZeneca also recently announced a $2 billion investment to develop a new manufacturing campus in the region.
While it’s still early, recent activity demonstrates that life science companies continue to see long term opportunity in the DC–Baltimore region. Follow Revista as we see how the rest of 2026 unfolds for this market!
